In animal models of NAFLD, GLP-1R agonists have been reported to reduce hepatic fat accumulation and alleviate hepatic damage by improving insulin resistance, adjusting lipid metabolism, and alleviating liver inflammation and oxidative stress. Here, INS is linked to metabolic dysfunction-associated steatotic liver disease.